Gritstone Oncology Inc

Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Gritstone Oncology reports strong financials and promising advancements in immunotherapy

Gritstone Oncology Inc showcases financial stability, progress in cancer immunotherapy, and advancements in infectious disease programs. Challenges include data requirements for ongoing studies, while opportunities lie in upcoming data presentations and exploring novel vaccine concepts.

Gritstone Oncology excels in Q1 with promising GRANITE program and samRNA advancements

Gritstone Oncology's Q1 2023 earnings call highlighted strong financials, progress in the GRANITE program, and advancements in the samRNA platform. Challenges include endpoint selection for Phase 3 study and managing pseudo progressors. Opportunities lie in combining immunotherapies for KRAS mutations and exploring adjuvant settings.

Gritstone Oncology reports positive Q1 results and eyes market expansion

Gritstone Oncology's Q1 2024 performance showcased positive outcomes in the GRANITE program and financial stability through strategic funding.
The company's strengths lie in promising immune responses, encouraging PFS data, and a proactive approach to clinical program advancement.
Challenges include data gaps in patient groups and uncertainties around future consortium data, while opportunities abound in market expansion and upcoming data releases.
Overall, Gritstone Oncology's focus on innovative cancer vaccine programs and financial prudence positions them well for future growth and clinical success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EMERYVILLE, Calif.--(BUSINESS WIRE)--Gritstone bio, Inc. (Nasdaq: GRTS) (“Gritstone” or the “Company”), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it has filed a voluntary petition under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Gritstone intends to use the court-administered restructuring process to preserve value and support its ongoing strategic alternati.

Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure

On Monday, Gritstone Bio Inc. GRTS revealed interim Phase 2 data from the ongoing Phase 2 study evaluating GRANITE, its individualized neoantigen-targeting immunotherapy, in frontline microsatellite-stable colorectal cancer (MSS-CRC).

Penny Stock Gritstone Bio Hires Advisor To Evaluate Options, Analyst Downgrades Stock As Data 'Insufficient To Excite Many Investors'

--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly

Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ:GRTS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 9, 2023 and February 29, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 6, 2024.

Investors Have The Opportunity To Lead The Gritstone bio, Inc. Securities Fraud Lawsuit With The Schall Law Firm

Gritstone bio Inc. (GRTS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.31 per share a year ago.

Gritstone bio Inc. (GRTS) Reports Q2 Loss, Misses Revenue Estimates

-- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 -- -- Recent KOL event and patient advocacy engagements underscore the unmet need for new treatment options in metastatic colorectal cancer --

Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Gritstone bio, Inc. (NASDAQ: GRTS) on behalf of long-term stockholders following a class action complaint that was filed against Gritstone on June 7, 2024 with a Class Period from March 9, 2023 to February 29, 2024. Our investigation concerns whether the board of directors of Gritstone have breached their fiduciary duties to the company.

GRITSTONE ALERT: Bragar Eagel & Squire, P.C. is Investigating Gritstone bio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ: GRTS ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 9, 2023 and February 29, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 6, 2024.

Investors Are Invited To Take The Lead In The Gritstone Bio Inc Securities Fraud Case With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 6, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gritstone-lawsuit-submission-form?prid=94180&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of Gritstone bio, Inc. Should Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights – GRTS

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ: GRTS ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 9, 2023 and February 29, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 6, 2024.

GRTS Investors Have The Opportunity To Lead Gritstone Bio Inc Securities Fraud Lawsuit With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 6, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gritstone-lawsuit-submission-form?prid=94140&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Gritstone bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - GRTS

LOS ANGELES--(BUSINESS WIRE)--GRTS Investors Have Opportunity to Join Gritstone bio, Inc. Fraud Investigation with the Schall Law Firm.

GRTS Investors Have Opportunity to Join Gritstone bio, Inc. Fraud Investigation with the Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 6, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gritstone-lawsuit-submission-form?prid=94073&wire=1 or contact Joseph E. Levi, Esq.

GRTS LAWSUIT ALERT: Levi & Korsinsky Notifies Gritstone bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

LOS ANGELES , Aug. 6, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ: GRTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 9, 2023 and February 29, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 6, 2024.

GRTS Investors Have the Opportunity to Lead Gritstone bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 6, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gritstone-lawsuit-submission-form?prid=94037&wire=1 or contact Joseph E. Levi, Esq.

Gritstone bio, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights - GRTS

NEW YORK , Aug. 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Gritstone bio, Inc. ("Gritstone" or the "Company") (NASDAQ: GRTS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Gritstone investors who were adversely affected by alleged securities fraud between March 9, 2023 and February 29, 2024.

Shareholders of Gritstone bio, Inc. Should Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights - GRTS

NEW YORK, NY / ACCESSWIRE / August 6, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gritstone-lawsuit-submission-form?prid=94016&wire=1 or contact Joseph E. Levi, Esq.

August 6, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - GRTS

NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ:GRTS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Gritstone securities between March 9, 2023, and February 29, 2024, inclusive (the "Class Period").

FINAL GRTS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Gritstone bio, Inc. Investors to Join the Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / August 5, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gritstone-lawsuit-submission-form?prid=93946&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Gritstone bio, Inc.(GRTS) Shareholders

NEW YORK, NY / ACCESSWIRE / August 5, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gritstone-lawsuit-submission-form?prid=93918&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Gritstone bio, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 6, 2024 - GRTS

NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Gritstone bio, Inc. ("Gritstone" or the "Company") (NASDAQ: GRTS) of a class action securities lawsuit.

Gritstone bio, Inc. Class Action: Levi & Korsinsky Reminds Gritstone Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 6, 2024 – GRTS

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Gritstone bio, Inc. (NASDAQ: GRTS) between March 9, 2023 and February 29, 2024. Gritstone describes itself as a “clinical-stage biotechnology company, [which] engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases.” For more information, submit a form, email attorney Phill.

GRTS Deadline: Rosen Law Firm Urges Gritstone bio, Inc. (NASDAQ: GRTS) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK, NY / ACCESSWIRE / August 5, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gritstone-lawsuit-submission-form?prid=93894&wire=1 or contact Joseph E. Levi, Esq.

Gritstone bio, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights - GRTS

BENSALEM, Pa., Aug. 5, 2024 /PRNewswire/ -- Law Offices of Howard G.

GRTS Investors Have Opportunity to Lead Gritstone bio, Inc. Securities Fraud Lawsuit

NEW YORK , Aug. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gritstone bio, Inc. (NASDAQ: GRTS). Shareholders who purchased shares of GRTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

News for Gritstone Oncology Inc Stock (GRTS)